Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
26 04 2022
Historique:
received: 21 09 2021
accepted: 04 04 2022
entrez: 27 4 2022
pubmed: 28 4 2022
medline: 29 4 2022
Statut: epublish

Résumé

Slowed clearance of amyloid β (Aβ) is believed to underlie the development of Aβ plaques that characterize Alzheimer's disease (AD). Aβ is cleared in part by the glymphatic system, a brain-wide network of perivascular pathways that supports the exchange of cerebrospinal and brain interstitial fluid. Glymphatic clearance, or perivascular CSF-interstitial fluid exchange, is dependent on the astroglial water channel aquaporin-4 (AQP4) as deletion of Aqp4 in mice slows perivascular exchange, impairs Aβ clearance, and promotes Aβ plaque formation. To define the role of AQP4 in human AD, we evaluated AQP4 expression and localization in a human post mortem case series. We then used the α-syntrophin (Snta1) knockout mouse model which lacks perivascular AQP4 localization to evaluate the effect that loss of perivascular AQP4 localization has on glymphatic CSF tracer distribution. Lastly, we crossed this line into a mouse model of amyloidosis (Tg2576 mice) to evaluate the effect of AQP4 localization on amyloid β levels. In the post mortem case series, we observed that the perivascular localization of AQP4 is reduced in frontal cortical gray matter of subjects with AD compared to cognitively intact subjects. This decline in perivascular AQP4 localization was associated with increasing Aβ and neurofibrillary pathological burden, and with cognitive decline prior to dementia onset. In rodent studies, Snta1 gene deletion slowed CSF tracer influx and interstitial tracer efflux from the mouse brain and increased amyloid β levels. These findings suggest that the loss of perivascular AQP4 localization may contribute to the development of AD pathology in human populations.

Sections du résumé

BACKGROUND
Slowed clearance of amyloid β (Aβ) is believed to underlie the development of Aβ plaques that characterize Alzheimer's disease (AD). Aβ is cleared in part by the glymphatic system, a brain-wide network of perivascular pathways that supports the exchange of cerebrospinal and brain interstitial fluid. Glymphatic clearance, or perivascular CSF-interstitial fluid exchange, is dependent on the astroglial water channel aquaporin-4 (AQP4) as deletion of Aqp4 in mice slows perivascular exchange, impairs Aβ clearance, and promotes Aβ plaque formation.
METHODS
To define the role of AQP4 in human AD, we evaluated AQP4 expression and localization in a human post mortem case series. We then used the α-syntrophin (Snta1) knockout mouse model which lacks perivascular AQP4 localization to evaluate the effect that loss of perivascular AQP4 localization has on glymphatic CSF tracer distribution. Lastly, we crossed this line into a mouse model of amyloidosis (Tg2576 mice) to evaluate the effect of AQP4 localization on amyloid β levels.
RESULTS
In the post mortem case series, we observed that the perivascular localization of AQP4 is reduced in frontal cortical gray matter of subjects with AD compared to cognitively intact subjects. This decline in perivascular AQP4 localization was associated with increasing Aβ and neurofibrillary pathological burden, and with cognitive decline prior to dementia onset. In rodent studies, Snta1 gene deletion slowed CSF tracer influx and interstitial tracer efflux from the mouse brain and increased amyloid β levels.
CONCLUSIONS
These findings suggest that the loss of perivascular AQP4 localization may contribute to the development of AD pathology in human populations.

Identifiants

pubmed: 35473943
doi: 10.1186/s13195-022-00999-5
pii: 10.1186/s13195-022-00999-5
pmc: PMC9040291
doi:

Substances chimiques

Amyloid beta-Peptides 0
Aqp4 protein, mouse 0
Aquaporin 4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

59

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS103740
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS065957
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG052354
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066509
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054456
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Neurobiol Aging. 2021 Jan;97:1-9
pubmed: 33068891
Alzheimers Dement. 2019 Jan;15(1):106-152
pubmed: 30321505
Acta Neuropathol Commun. 2019 May 8;7(1):74
pubmed: 31068220
Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):265-269
pubmed: 30052535
Cell Discov. 2017 Mar 28;3:17005
pubmed: 28377822
Biochim Biophys Acta. 2016 Mar;1862(3):442-51
pubmed: 26499397
J Neurosci. 2015 Jan 14;35(2):518-26
pubmed: 25589747
Science. 2013 Oct 18;342(6156):373-7
pubmed: 24136970
Transl Psychiatry. 2018 Feb 26;8(1):47
pubmed: 29479071
Glia. 2022 Mar;70(3):466-490
pubmed: 34773297
Science. 2010 Dec 24;330(6012):1774
pubmed: 21148344
Neurobiol Dis. 2016 Sep;93:215-25
pubmed: 27234656
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
JAMA Neurol. 2019 Aug 01;76(8):915-924
pubmed: 31157827
J Biol Chem. 2016 Sep 9;291(37):19590-606
pubmed: 27458018
J Neuropathol Exp Neurol. 2012 May;71(5):362-81
pubmed: 22487856
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14108-13
pubmed: 11717465
J Neurosci Res. 2018 Feb;96(2):180-193
pubmed: 28509351
Neurobiol Aging. 2009 Jul;30(7):1026-36
pubmed: 19376612
J Biol Chem. 2015 Jul 3;290(27):16873-81
pubmed: 26013827
J Cell Biol. 2000 Sep 18;150(6):1385-98
pubmed: 10995443
Mol Neurodegener. 2015 Nov 02;10:58
pubmed: 26526066
Elife. 2017 Aug 21;6:
pubmed: 28826498
Cell. 2020 May 14;181(4):784-799.e19
pubmed: 32413299
Nature. 2013 Sep 5;501(7465):45-51
pubmed: 24005412
JAMA Neurol. 2017 Jan 01;74(1):91-99
pubmed: 27893874
Brain. 2020 Aug 1;143(8):2576-2593
pubmed: 32705145
Sci Transl Med. 2012 Aug 15;4(147):147ra111
pubmed: 22896675
Methods. 2002 Oct;28(2):267-75
pubmed: 12413426
J Clin Invest. 2000 Dec;106(12):1489-99
pubmed: 11120756
Biochim Biophys Acta. 2008 Apr;1778(4):1181-9
pubmed: 18179769
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2106-11
pubmed: 12578959
Mol Ther. 2013 Aug;21(8):1470-1
pubmed: 23903572
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Hippocampus. 2016 Feb;26(2):194-210
pubmed: 26235241
J Neurosci. 2014 Dec 3;34(49):16180-93
pubmed: 25471560
Nat Biotechnol. 2016 Feb;34(2):204-9
pubmed: 26829320
Front Aging Neurosci. 2016 Jul 05;8:160
pubmed: 27458370
J Cereb Blood Flow Metab. 2013 Jun;33(6):834-45
pubmed: 23443171
Elife. 2018 Dec 18;7:
pubmed: 30561329
J Cell Biol. 1980 Jun;85(3):890-902
pubmed: 6248568
Neurol Sci. 2011 Feb;32(1):113-6
pubmed: 20924629
Physiol Rev. 2019 Jan 1;99(1):21-78
pubmed: 30280653
Ann Neurol. 2015 Sep;78(3):439-53
pubmed: 26040676
J Neurosci. 2017 Mar 15;37(11):2870-2877
pubmed: 28188218
Glia. 2017 May;65(5):790-803
pubmed: 28206694
Physiol Rev. 2013 Oct;93(4):1543-62
pubmed: 24137016
Nat Med. 2014 Feb;20(2):130-8
pubmed: 24504409
Alzheimers Dement (N Y). 2017 May 26;3(3):348-359
pubmed: 29067342
Science. 1996 Oct 4;274(5284):99-102
pubmed: 8810256
Nat Med. 2003 Apr;9(4):453-7
pubmed: 12612547
Cell Rep. 2019 Jan 15;26(3):594-607.e7
pubmed: 30650354
Neuroscience. 2006;138(2):501-10
pubmed: 16414198
Mol Neurobiol. 2020 Nov;57(11):4720-4734
pubmed: 32783141
Gene Ther. 1999 Jun;6(6):973-85
pubmed: 10455399
Sci Rep. 2018 Aug 17;8(1):12389
pubmed: 30120299
Glia. 2021 Jan;69(1):28-41
pubmed: 32506554
J Neurosci. 2012 Dec 12;32(50):17948-60
pubmed: 23238711
Eur J Neurosci. 2017 Nov;46(9):2542-2547
pubmed: 28925524
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879
J Exp Med. 2007 Aug 6;204(8):1999-2008
pubmed: 17664291
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13609-14
pubmed: 14597700
Lancet Neurol. 2017 Nov;16(11):862-864
pubmed: 29029840
Ann Neurol. 2014 Dec;76(6):845-61
pubmed: 25204284

Auteurs

Matthew Simon (M)

Neuroscience Graduate Program, Oregon Health & Science University, Portland, OR, USA.
Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.

Marie Xun Wang (MX)

Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA. xunw@uw.edu.
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. xunw@uw.edu.

Ozama Ismail (O)

Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.
Center for Advanced Biomedical Imaging, University College London, London, UK.

Molly Braun (M)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 S Columbian Wy., Seattle, WA, 98108, USA.

Abigail G Schindler (AG)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.
VISN 20 Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, WA, USA.

Jesica Reemmer (J)

Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR, USA.

Zhongya Wang (Z)

Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR, USA.

Mariya A Haveliwala (MA)

VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 S Columbian Wy., Seattle, WA, 98108, USA.

Ryan P O'Boyle (RP)

VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 S Columbian Wy., Seattle, WA, 98108, USA.

Warren Y Han (WY)

VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 S Columbian Wy., Seattle, WA, 98108, USA.

Natalie Roese (N)

Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA.

Marjorie Grafe (M)

Department of Pathology, Oregon Health & Science University, Portland, OR, USA.

Randall Woltjer (R)

Department of Pathology, Oregon Health & Science University, Portland, OR, USA.

Detlev Boison (D)

Department of Neurosurgery, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, USA.

Jeffrey J Iliff (JJ)

Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA. jiliff@uw.edu.
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. jiliff@uw.edu.
VISN 20 Mental Illness Research, Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 S Columbian Wy., Seattle, WA, 98108, USA. jiliff@uw.edu.
Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA. jiliff@uw.edu.
Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA. jiliff@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH